Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2009, 34(2): 106
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2009 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2009.034.02.1340647
Dulsat, C., Mealy, N., Castaner, R.
Tumor development is usually triggered by abnormalities in complex signaling pathways involved in normal cell growth, activity and function. Src kinase has been identified as a critical signaling pathway involved in tumor cell migration and invasion in multiple cancers, therefore representing a promising pharmacotherapeutic target. To date, no inhibitor of Src kinase has been granted marketing approval. Saracatinib (AZD-0530) is an oral, highly selective dual inhibitor of the Src and ABL kinases. This monograph highlights the preclinical and clinical studies completed to date for saracatinib, which is currently in phase II clinical development for ovarian, breast, prostate, colorectal, lung, bone, pancreatic, skin, gastric, thymic and head and neck cancers.

Full Text: HTMLPDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences